ArticleThe Journal of clinical investigation2003
Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.
Article in The Journal of clinical investigation, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 108 citations in OpenAlex.
- Research progress of biomaterials and innovative technologies in urinary tissue engineering.Frontiers in bioengineering and biotechnology · 2023Review
- The TGM2 inhibitor cysteamine hydrochloride does not impact corneal epithelial and stromal wound healing in vitro and in vivo.Experimental eye research · 2023Article
- Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand.RSC advances · 2022Article
- Review
- Tranglutaminase 2 contributes to the asthmatic inflammation by modulating activation of alveolar macrophages.Immunity, inflammation and disease · 2021Article
- Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.The ocular surface · 2021Review
- The proteomic profile of a mouse model of proliferative vitreoretinopathy.FEBS open bio · 2017Article
- An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.Paediatric drugs · 2016Review
- Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2.Cellular and molecular life sciences : CMLS · 2015Review
- The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibers.Biomaterials · 2014Article
- Transglutaminase II/microRNA-218/-181a loop regulates positive feedback relationship between allergic inflammation and tumor metastasis.The Journal of biological chemistry · 2014Article
- Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.Journal of cancer research and clinical oncology · 2014Article
- Intimal hyperplasia in loop-injured carotid arteries is attenuated in transglutaminase 2-null mice.Journal of Korean medical science · 2014Article
- Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family.TheScientificWorldJournal · 2014Review
- Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.Rejuvenation research · 2013Review
- Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.Journal of cancer research and clinical oncology · 2013Article
- Airway epithelial cells initiate the allergen response through transglutaminase 2 by inducing IL-33 expression and a subsequent Th2 response.Respiratory research · 2013Article
- Epithelial regulation of eicosanoid production in asthma.Pulmonary pharmacology & therapeutics · 2012Review
- Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death.Molecules and cells · 2012Article
- Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report.BMC biotechnology · 2011Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroidal anti-inflammatory drugs induce proteins that inhibit phospholipase A(2) (PLA(2)), including uteroglobin and lipocortin-1 (annexin I). Uteroglobin and lipocortin-1 retain several conserved sequences. Based on these sequences, several nonapeptides (antiflammins) were synthesized. These nonapeptides were shown to have anti-inflammatory effects in vitro and in vivo, possibly by inhibiting PLA(2). Subsequent research showed that PLA(2) is activated by transglutaminase 2 (TGase 2). We hypothesize here that TGase 2 inhibitors may increase the anti-inflammatory efficacy of inhibiting PLA(2) activity. To test this theory, we constructed recombinant peptides containing sequences from pro-elafin (for inhibition of TGase 2), and from lipocortin-1, lipocortin-5, and uteroglobin (for inhibition of PLA(2)). The recombinant peptides, which had dual inhibitory effects on purified TGase 2 and PLA(2), reversed the inflammation of allergic conjunctivitis to ragweed in a guinea pig model. The present work suggests that novel recombinant peptides may be safe and effective agents for the treatment of various inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.